Sponsored Links
| Alnylam Presents Phase I Data For ALN-VSP, An RNAi Therapeutic For The Treatment Of Liver Cancers, At ASCO Meeting |
 |
 |
 |
| Medical News - Liver Disease and Hepatitis | |||
|
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement... Read more: Liver Disease / Hepatitis News From Medical News Today
|